Endologix Reports 42% Revenue Growth in the 2009 First Quarter
IRVINE, Calif., Apr 23, 2009 (BUSINESS WIRE) -- Endologix, Inc. (NASDAQ: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three months ended March 31, 2009.
"We are reporting another quarter of record sales, with total revenue increasing 42% year-over-year and 11% sequentially from the 2008 fourth quarter," said John McDermott, Endologix President and Chief Executive Officer. "Domestic revenue grew 49% versus the prior-year and 11% sequentially due to increased sales force productivity and new product introductions.
"The 2009 first quarter was the first full sales period to include our surprarenal extensions and Powerlink XL(R) products, which open new market opportunities for Endologix. Last month, we initiated the full domestic launch of our novel IntuiTrak(TM) Delivery System that features improved delivery and deployment of our Powerlink(R) System," he added. "We are currently conducting a limited release with the IntuiTrak Express Delivery System for the Powerlink XL, which is slated for full domestic commercialization in the third quarter."
First Quarter Financial Results
Total revenue in the first quarter of 2009 was $11.8 million, a 42% increase from $8.3 million in the first quarter of 2008, and an 11% increase from $10.7 million in the fourth quarter of 2008. Domestic revenue of $10.2 million represented a 49% increase compared with $6.8 million in the 2008 first quarter, and 11% from $9.1 million in the 2008 fourth quarter. International revenue increased to $1.7 million, up 13% compared with $1.5 million during the comparable quarter last year and up 7% from $1.6 million in the fourth quarter of 2008.
Gross profit was $8.9 million in the first quarter of 2009 which represented a gross margin of 75% of revenue. This compares with $5.8 million and 70%, respectively, in the first quarter of 2008.
Total operating expenses were $10.0 million in the first quarter of 2009, versus $9.6 million in the first quarter of 2008. Marketing and sales expenses increased to $6.6 million in the first quarter of 2009 from $5.8 million in the comparable quarter last year. Research, development and clinical expenses for the first three months of 2009 were $1.4 million, versus $1.5 million in the same period last year, and general and administrative expenses were $2.1 million, versus $2.3 million for the prior year period.
Endologix reported a net loss for the first quarter of 2009 of $1.2 million, or $0.03 per share, compared with a net loss of $3.7 million, or $0.09 per share, for the first quarter of 2008.
Total cash and cash equivalents were $6.8 million as of March 31, 2009, compared with total cash and cash equivalents of $7.6 million as of December 31, 2008.
"As a result of strong revenue growth, gross margin improvement and our ability to control expenses during the 2009 first quarter, we were able to achieve positive cash flow from operations in the interim months of February and March," stated Endologix Chief Financial Officer Robert Krist. "We believe this is a strong indication that we are on track to achieve our previously announced goal of having positive cash flow from operations for the second quarter of 2009."
Conference Call Information
Endologix management will host a conference call to discuss these topics today beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). To participate via telephone please call (888) 463-4487 from the U.S. or (706) 634-5615 from outside the U.S. A telephone replay will be available for two days following the completion of the call by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside the U.S., and entering reservation number 92665041. The conference call will be broadcast live over the Internet at www.endologix.com and will be available for 14 days.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the full commercialization of the IntuiTrak Express Delivery System for the Powerlink XL and achieving positive cash flow from operations for the second quarter of 2009, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors.The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended
|Domestic Product Revenue||$||10,176||$||6,849|
|Non - U.S. Product Revenue||1,658||1,468|
|Total Product Revenue:||11,834||8,317|
|Cost of product revenue||2,905||2,531|
|Gross profit as a % of total revenue||75||%||70||%|
|Research, development and clinical||$||1,355||$||1,498|
|Marketing and sales||6,622||5,800|
|General and administrative||2,068||2,272|
|Total operating expenses||10,045||9,570|
|Loss from operations||$||(1,116||)||$||(3,772||)|
|Basic and diluted net loss per share||($0.03||)||($0.09||)|
|Shares used in computing basic and diluted net loss per share||43,345||42,953|
CONDENSED CONSOLIDATED BALANCE SHEETS
|March 31, |
|December 31, 2008|
|Cash and cash equivalents||$||6,847||$||7,611|
|Restricted cash equivalents||500||500|
|Accounts receivable, net||7,283||6,371|
|Other current assets||425||443|
|Total current assets||22,482||22,027|
|Property and equipment, net||2,770||2,993|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable and accrued expenses||$||5,752||$||5,401|
|Current portion of long term debt||1,000||750|
|Long term liabilities:|
|Long term debt||4,000||4,250|
|Other long term liabilities||1,029||1,045|
|Long term liabilities||5,029||5,295|
|Common stock, $.001 par value; 60,000 shares authorized, and 44,365 and 44,365 shares issued, and 43,870 and 43,870 outstanding|
|Additional paid-in capital||170,989||170,239|
Treasury stock at cost, 495 shares
|Accumulated other comprehensive income||(108||)||(75||)|
|Total stockholders' equity||25,356||25,817|
|Total Liabilities and Stockholders' Equity||$||37,137||$||37,263|
SOURCE: Endologix, Inc.
Robert Krist, CFO, 949-595-7200
Lippert/Heilshorn & Associates, Inc.
Bruce Voss or Jody Cain, 310-691-7100
Copyright Business Wire 2009